Biopharmaceutical company CARsgen Therapeutics reported on Monday the receipt of the Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) in China for the AB011 humanized claudin18.2 monoclonal antibody.
The company added that the AB011 humanized claudin18.2 monoclonal antibody has received the NMPA clearance for the treatment of patients suffering from advanced gastric and pancreatic adenocarcinoma in China.
According to the company, AB011 is the first humanized monoclonal antibody targeting claudin18.2 entering clinical trials.
CARsgen Therapeutics stated that claudin18.2 is a stomach-specific isoform of claudin-18 (1-3). It is only expressed in short-lived differentiated cells and not expressed in the stem cell zone of the stomach mucosa. Pathologically, it is highly expressed in a variety of cancer types, including gastric and pancreatic cancer. These characteristics suggest that claudin18.2 is a rational target for cancer.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval